Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors December 10, 2024
Relay Therapeutics & Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors December 10, 2024
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials December 10, 2024
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target December 10, 2024
Olema Oncology Announces New CTA and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement December 4, 2024
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer December 4, 2024
Successful Completion of $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline December 4, 2024
Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio December 4, 2024
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies December 4, 2024
Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer November 26, 2024
Incyclix Bio and Lilly to test INX-315 + Verzenio and Fulvestrant in HR+/HER2- Breast Cancer November 26, 2024
Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate November 26, 2024
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline November 26, 2024
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific ADC November 26, 2024
Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies November 26, 2024
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias November 26, 2024
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer November 26, 2024
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology November 26, 2024
IDEAYA Nominates IDE034, a B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen November 19, 2024
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib November 19, 2024
